RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
Jefferies Remains a Buy on Biogen (BIIB)
Biogen Analyst Ratings
Mizuho Maintains Outperform on Biogen, Lowers Price Target to $207
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Announces Target Price $207
Mizuho Securities Adjusts Price Target on Biogen to $207 From $251
Biogen Price Target Maintained With a $270.00/Share by Needham
Biogen Analyst Ratings
TD Cowen Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $275
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $204 to $300
Biogen (BIIB) Gets a Buy From TD Cowen
Biogen Is Maintained at Outperform by Baird
Cautious Optimism for Biogen: Hold Rating Amidst European Approval Developments
Biogen Analyst Ratings
Citi Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $190
Biogen Initiated With a Neutral at Citi
Argus Cuts Biogen's Price Target to $200 From $250
J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $210